• 提示：详情请下载说明书。

• 产品描述： Osimertinib mesylate (AZD9291) 是osimertinib的甲磺酸盐形式，是口服的第三代 epidermal growth factor receptor (EGFR) 酪氨酸激酶(TKI)抑制剂

• 靶点： EGFR

• 体外研究：
  Osimertinib-resistant lung adenocarcinoma (LUAD) cells express higher level of METTL7B in comparison to Osimertinib-sensitive cells. Knock-down of METTL7B by GNC-siRNA re-sensitized LUAD cells to osimertinib

• 体内研究：
  METTL7B is significantly increased in both mRNA and protein level in osimertinib -resistant xenografts as compared with those in osimertinib-sensitive xenografts. In LUAD CDX mouse model, combination treatment with GNC-siMETTL7B (6 mg siRNA per mouse equivalent) significantly suppresses tumor growth as compared with treatment of osimertinib (30 mg/kg) alone.

• 细胞实验： Cell lines: lung adenocarcinoma (LUAD) cell lines Concentrations: 0.001 -1 µM Incubation Time: 72 h Method: Cells are plated at a density of 3,000 cells/well in 96 well plates. Osimertinib is added to the medium and treated for 72 h. Cell viability assays are performed by Cell Counting Kit-8.

• 参考文献：
  1. Song H, et al. Methyltransferase like 7B is a potential therapeutic target for reversing EGFR-TKIs resistance in lung adenocarcinoma. Mol Cancer. 2022 Feb 10;21(1):43. 2. Alessandro Leonetti, et al. Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer. Br J Cancer . 2019 Oct;121(9):725-737.

• 溶解性： Soluble  in  DMSO

• 保存条件： -20℃

• 配置溶液浓度参考：
  

  	1mg	5mg	10mg
  1 mM	1.679 ml	8.393 ml	16.787 ml
  5 mM	0.336 ml	1.679 ml	3.357 ml
  10 mM	0.168 ml	0.839 ml	1.679 ml
  50 mM	0.034 ml	0.168 ml	0.336 ml

• 注意：部分产品我司仅能提供部分信息，我司不保证所提供信息的权威性，仅供客户参考交流研究之用。

输入产品批号：

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系，公式为：

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)

• pg ng μg mg g kg =
  fM pM nM μM mM M *
  nL μL mL L *